JPRN-UMIN000014940已完成未知
A Multicenter, single blind, dose-escalation, Investigator initiated trial for single intravenous administration of NK-104-NP to male adult Healthy volunteers - Intravenous Administration of NK-104-NP to healthy volunteers
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 40years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1)A person who has history of drug allergy. 2)A person who has hypersensitivity including allergy (except asymptomatic allergy). 3)A person who used other therapeutic drugs within 2 weeks or who needs other therapeutic drugs during the clinical trial participation period. 4)A person who used other OTC drugs within a week or who needs other OTC drugs during the clinical trial participation period. 5)A person who donated over 200 mL of whole blood within a month, who experienced plasmapheresis/platelet apheresis within 2 weeks or who donated over 400 mL of whole blood within 3 months. 6)A person who was entolled and given new drugs in other clinical trials within four months before this clinical trial or a person who participates in other clinical trials at the same time with this clinical trial. 7)A person whose percutaneous arterial oxygen saturation is less than 95%. 8)A person with alcohol or drug dependency. 9)A person who is positive for drug abuse tests. 10)A person who is positive for the following tests: HBs antigen, HCV antibody, HIV antigen/antibody or syphilis serum reaction. 11)A person who cannot prevent pregnancy during 6 months after this clinical trial. 12)A person assessed as ineligible for enrollment by investigators of this clinical trial.
研究者
相似试验
进行中（未招募）
不适用
Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU) - AECUDATTChronic urticaria is characterized by the spontaneous development of wheal and flare type skin reactions.MedDRA version: 9.1Level: LLTClassification code 10009869Term: Cold urticariaEUCTR2008-005746-22-DEAllergie-Centrum-Charite, Department of Dermatology, Charite - Universitätsmedizin Berlin30
进行中（未招募）
1 期
A first-in-human study to investigate the safety and tolerability of a new antibody-guided drug delivery treatment for patients with therapy resistant ovarian or lung cancer.Platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC)CTIS2024-511074-80-01Tubulis GmbH140
进行中（未招募）
不适用
A single center, open-label, dose escalation study of the safety and pharmacokinetics of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) for the treatment of patients with alpha-mannosidosis.Treatment of alpha-MannosidosisEUCTR2010-022084-36-DKZymenex A/S10
已完成
1 期
A Phase 1, Single-Center, Dose-Escalation and Fixed-Dose Crossover, Cohort Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF329 vs oral hydromorphone hydrochloride (HCl) in Healthy SubjectsACTRN12610000721000PharmacoFore, Inc.80
未知
2 期
A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Pediatric SubjectsJPRN-jRCT2080221032ovartis Pharma K.K.120